In recently concluded, but still undisclosed, trade agreement negotiations with the United States, the South Korean government demanded the capacity to establish a positive-list cost-effectiveness and reference pricing system (as exists in Australia) that values “innovation” in health care technology, for all citizens, rich and poor alike, by expert evaluation of its “objectively demonstrated therapeutic significance.” Yet US negotiators, contrary to resolutions of the Democrat-controlled Congress, resisted this Korean approach and instead imposed a mechanism for “evergreening” pharmaceutical patent royalties likely to impede access by the poor to “essential” generic medicines. Such developments are symptomatic of those carefully highlighted by Theodore MacDonald in Health, Trade and Human Rights.
Faunce TA. Health, Trade and Human Rights. JAMA. 2007;297(20):2287–2291. doi:10.1001/jama.297.20.2288
Customize your JAMA Network experience by selecting one or more topics from the list below.